Evofem Terminates Phexxi License Deal with 03 Life Sciences
Ticker: EVFM · Form: 8-K · Filed: Oct 31, 2024 · CIK: 1618835
Sentiment: bearish
Topics: termination, licensing, strategy-change
TL;DR
Evofem dumped 03 Life Sciences over breach, Phexxi US strategy now TBD.
AI Summary
Evofem Biosciences, Inc. announced on October 27, 2024, the termination of its exclusive license agreement with 03 Life Sciences for the commercialization of Phexxi in the United States. This termination is effective immediately and follows a material breach by 03 Life Sciences. Evofem is now seeking alternative strategies for Phexxi's US market presence.
Why It Matters
The termination of this key license agreement significantly impacts Evofem's strategy for Phexxi in the US market, requiring them to find new avenues for commercialization.
Risk Assessment
Risk Level: high — The termination of a major license agreement creates significant uncertainty regarding the future commercialization of the company's primary product.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- 03 Life Sciences (company) — Former licensee
- Phexxi (product) — Product subject to license agreement
- October 27, 2024 (date) — Effective date of termination
FAQ
What was the reason for terminating the license agreement with 03 Life Sciences?
The agreement was terminated due to a material breach by 03 Life Sciences.
What product was covered by the license agreement?
The license agreement was for the commercialization of Phexxi in the United States.
When did the termination of the license agreement become effective?
The termination was effective immediately as of October 27, 2024.
What is Evofem Biosciences' next step regarding Phexxi in the US?
Evofem Biosciences is currently exploring alternative strategies for the commercialization of Phexxi in the United States.
What is the former name of Evofem Biosciences?
The former name of Evofem Biosciences was Neothetics, Inc., with a name change date of September 5, 2014.
Filing Stats: 1,342 words · 5 min read · ~4 pages · Grade level 14.4 · Accepted 2024-10-31 17:20:02
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex10-1.htm (EX-10.1) — 94KB
- 0001493152-24-043241.txt ( ) — 328KB
- evfm-20241027.xsd (EX-101.SCH) — 3KB
- evfm-20241027_lab.xml (EX-101.LAB) — 33KB
- evfm-20241027_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: October 31, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer